On Tuesday, Jazz Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 66 to 72.
How To Invest In Stocks In Both Bull And Bear Markets
This proprietary rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an RS Rating of at least 80 in the early stages of their moves. See if Jazz Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
Jazz Pharmaceuticals is building a cup with handle with a 133.00 buy point. See if it can break out in volume at least 40% above average.
Top and bottom line growth moved higher last quarter. Earnings were up 0%, compared to -36% in the prior report. Revenue increased from 0% to 2%.
The company holds the No. 10 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Novartis ADR and AbbVie are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
